.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,854,290

« Back to Dashboard
Patent 5,854,290 protects INTUNIV and is included in one NDA. There has been one Paragraph IV challenge on Intuniv.

Protection for INTUNIV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 5,854,290

Title: Use of guanfacine in the treatment of behavioral disorders
Abstract:Disclosed is a method of treating disorders which have prominent symptoms of behavioral disinhibition (e.g., Attention-Deficit Hyperactivity Disorder, Conduct Disorder, Oppositional Defiant Disorder, Tourette's Syndrome, Lesch-Nyhan Syndrome, or the disinhibitory symptoms accompanying Post-traumatic Stress Disorder or dementia) in a primate with minimal sedative side effects by administering thereto a therapeutically effective amount of guanfacine.
Inventor(s): Arnsten; Amy F. T. (Bethany, CT), Goldman-Rakic; Patricia S. (New Haven, CT), Hunt; Robert H. (Nashville, TN)
Assignee: Arnsten; Amy F. T. (Bethany, CT) Goldman-Rakic; Patricia (New Haven, CT) Hunt; Robert H. (Nashville, TN)
Application Number:08/531,643
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Shire
INTUNIV
guanfacine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022037-001Sep 2, 2009RXNo5,854,290*PED► subscribeY
Shire
INTUNIV
guanfacine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022037-002Sep 2, 2009RXNo5,854,290*PED► subscribeY
Shire
INTUNIV
guanfacine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022037-003Sep 2, 2009RXNo5,854,290*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc